Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study of BON-C1393 in Adults With Advanced Solid Tumors

13. november 2026 oppdatert av: BeOne Medicines

A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BON-C1393 in Patients With Selected Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BON-C1393 monotherapy or in combination with other anticancer regimens in adults with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Dose Exploration) and Phase 1b (Dose Expansion).

Studieoversikt

Status

Har ikke rekruttert ennå

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Advanced solid tumors are malignant cancers that develop in organs of the body. They spread to other parts of the body and may reoccur after treatment, or no longer respond to available therapies or surgery. Many people with advanced solid tumors have limited treatment options, and their cancer may continue to grow or spread. Therefore, there is an ongoing need to develop novel therapies that may improve tumor control and prolong survival.

BON-C1393 is a targeted cancer medicine called an antibody-drug conjugate (ADC). An ADC consists of an antibody linked to a drug that can kill cancer cells. The antibody part of BON-C1393 attaches to proteins that are found on the surface of cancer cells. After it attaches to these proteins, BON-C1393 enters the cancer cell where the drug causes DNA damage and cell death.

The purpose of this study is to test whether BON-C1393 is safe and if it can help treat adults with selected advanced solid tumors.

This study consists of 2 parts, one called dose escalation and dose exploration (Phase 1a) and one called dose expansion (Phase 1b). During the dose escalation and dose exploration part, the study doctors will test different doses of the study drug to find the recommended dose that people can take without having serious side effects.

During the dose expansion part, the study doctors will test the study drug in a larger number of people using the doses identified from Phase 1a. The study will enroll adults with advanced solid tumors at multiple centers in the Asia-Pacific region.

The overall time to participate in this study is approximately 9 months for Phase 1a and approximately 12 months for Phase 1b. Participants will make regular visits to the clinic for treatment, health checks, blood tests, and tumor and imaging tests.

Studietype

Intervensjonell

Registrering (Antatt)

90

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Histologically or cytologically confirmed, unresectable, locally advanced, or metastatic solid tumor intolerant, refractory to or progressing after standard systemic therapies.

  • Must be able to provide archival tumor tissue (formalin-fixed, paraffin-embedded tissue block (FFPE) block or approximately 10-15 freshly cut unstained FFPE slides)

  • Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.0

  • Must have adequate organ function as indicated by the following laboratory values ≤ 7 days before the first dose of study drug(s):

    a. Must not have required blood transfusion or growth factor support ≤ 14 days before sample collection at screening for the following:

  • Absolute neutrophil count (ANC) ≥ 1.5 × 109/L.

  • Platelets ≥ 100 × 109/L.

  • Hemoglobin ≥ 90 g/L. b. Estimated glomerular filtration rate (GFR) ≥ 50 mL/min, as determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) c. Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN) (total bilirubin must be ≤ 3 × ULN with direct bilirubin ≤ 1.5 × ULN for patients with Gilbert's syndrome).

    d. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN or < 5 × ULN if hepatic metastases are present.

    e. Albumin ≥ 2.0 g/dL. f. In Phase 1b Part D, for patients receiving combination therapy with bevacizumab, additional inclusion criteria are listed below:

  • Urine dipstick for proteinuria < 2+ (within 7 days prior to initiation of study treatment). Patients discovered to have 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate < 1 g of protein in 24 hours.

  • Coagulation parameters: international normalized ratio (INR) of ≤ 1.5 (or an in-range INR of ≤ 3, if a patient is on a stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) < 1.2 × ULN.

  • Female of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for ≥ 7 months after the last dose of BON-C1393, for ≥ 6 months after the last dose of bevacizumab or capecitabine, whichever comes later. They must also have a negative urine or serum pregnancy test result ≤ 3 days before first dose of study drug/treatment.

  • Nonsterile male must be willing to use condom and refrain from sperm donation for the duration of the study and for ≥ 4 months after the last dose of BON-C1393, for ≥ 3 months after the last dose of capecitabine, whichever comes later.

Exclusion Criteria:

  • Prior treatment with any B7 homolog 3 (B7-H3) or integrin beta-6 (ITGB-6) -targeted antibody-drug conjugate (ADCs) or ADCs containing topoisomerase inhibitor (TOP) inhibitor as payload.
  • History of severe allergic reactions, severe reaction to infusion, or hypersensitivity to the active ingredient and excipients of the study drug(s) or protein-based therapeutics.
  • Unable to comply with the requirements of the protocol, unless the written approval of the medical monitor has been obtained before informed consent.
  • Active hepatitis C.
  • Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
  • Any major surgical procedure ≤ 28 days (or ≤ 14 days for low-invasive cases [eg, colostomy]) before the first dose of study drug. Must have recovered adequately from the surgery and/or complications from the surgical procedures before the first dose of study drug/treatment.

Any of following treatments before the first dose of study drug:

  1. Prior systemic anticancer therapy (including targeted therapy and immunomodulators [eg, interleukin (IL), interferon, thymosin, etc]) ≤ 14 days, ≤ 28 days for immuno-oncological antibody, ≤14 days or 5 half-lives (whichever is shorter) for chemotherapy, ADCs, or investigational therapy.

  2. Radiation therapy (curative) and palliative radiation therapy to the chest ≤ 4 weeks; ≤ 2 weeks for palliative radiation therapy to other areas (ie, limited field and 10 or fewer days or fractions) including whole-brain radiotherapy.

  3. Chinese patent medicine with anticancer activity approved by the China National Medical Products Administration (NMPA) (regardless of the type of cancer) ≤ 14 days.

  4. Herbal remedies with immune-stimulating properties (eg, mistletoe extract) or that are known to potentially interfere with liver or other major organ functions (eg, hypericin) ≤ 14 days or 5 half-lives, whichever is shorter or known.

    • Ongoing treatment with a strong cytochrome cytochrome (CYP)3A inhibitor, or strong CYP3A inducer, or strong CYP1A2 inhibitor, or strong CYP1A2 inducer.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Phase 1a Part A: Monotherapy Dose Escalation

Sequential cohorts of increasing dose levels of BON-C1393 will be evaluated.

Administered intravenously

Eksperimentell: Phase 1a Part B: Monotherapy Dose Exploration

Participants with select advanced solid tumors will receive BON-C1393 at 2 - 3 selected dose levels that have been determined to be safe in Part A.

Administered intravenously

Eksperimentell: Phase 1b Part C: Monotherapy Dose Expansion

Participants with select advanced solid tumors will receive BON-C1393 as monotherapy at the recommended doses for expansion (RDFEs) identified in Phase 1a.

Administered intravenously

Eksperimentell: Phase 1b Part D: Dose Expansion Combination Therapy

Participants with select advanced solid tumors will receive BON-C1393 in combination with bevacizumab and capecitabine.

Administered orally

Administered intravenously

Administered intravenously

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Phase 1a: Number of Participants with Dose-Limiting Toxicities (DLTs)
Tidsramme: Approximately 1 month
Approximately 1 month
Phase 1a: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs)
Tidsramme: Up to approximately 9 months
Up to approximately 9 months
Phase 1b: Overall Response Rate (ORR) Assessed by the Investigator
Tidsramme: Up to approximately 12 months

ORR is defined as the percentage of participants with a best overall response (BOR) of partial response (PR) or better per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Up to approximately 12 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Phase 1a: Overall Response Rate (ORR) Assessed by the Investigator
Tidsramme: Up to approximately 9 months

ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Up to approximately 9 months
Phase 1a: Duration of Response (DOR) Assessed by the Investigator
Tidsramme: Up to approximately 9 months

DOR is defined as the time from the first determination of an objective response until the first documentation of disease progression or death due to any cause, whichever occurs first.

Up to approximately 9 months
Phase 1b: Duration of Response (DOR) Assessed by the Investigator
Tidsramme: Up to approximately 12 months

DOR is defined as the time from the first determination of an objective response until the first documentation of disease progression or death due to any cause, whichever occurs first.

Up to approximately 12 months
Phase 1a: Disease Control Rate (DCR) Assessed by the Investigator
Tidsramme: Up to approximately 9 months

DCR is defined as the percentage of participants with a BOR of a CR, PR, or stable disease (SD) per RECIST v1.1.

Up to approximately 9 months
Phase 1b: Disease Control Rate (DCR) at 12 Weeks Assessed by the Investigator
Tidsramme: 12 Weeks

DCR at 12 weeks is defined as the percentage of participants with CR, PR, or SD per RECIST v1.1, and are alive and progression-free at Week 12.

12 Weeks
Phase 1b: Disease Control Rate (DCR) at 24 Weeks Assessed by the Investigator
Tidsramme: 24 weeks

DCR at 24 weeks is defined as the percentage of participants with CR, PR, or SD according to RECIST v1.1, and are alive and progression-free at the Week 24.

24 weeks
Phase 1b: Progression-free Survival (PFS) Assessed by the Investigator
Tidsramme: Up to approximately 12 months

PFS is defined as the time from the date of the first administration of study drug to the date of the first documentation of disease progression or death due to any cause, whichever occurs first.

Up to approximately 12 months
Area Under the Concentration Time Curve (AUC) of BON-C1393
Tidsramme: Up to approximately 3 months
Up to approximately 3 months
Maximum Observed Plasma Concentration (Cmax) of BON-C1393
Tidsramme: Up to approximately 8 months
Up to approximately 8 months
Time to Maximum Plasma Concentration (Tmax) of BON-C1393
Tidsramme: Up to approximately 8 months
Up to approximately 8 months
Terminal Half-Life (t1/2) of BON-C1393
Tidsramme: Up to approximately 3 months
Up to approximately 3 months
Plasma Concentrations of BON-C1393
Tidsramme: Up to approximately 12 months
Up to approximately 12 months
Phase 1b: Number of Participants with Adverse Events
Tidsramme: Up to approximately 12 months
Up to approximately 12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Study Director, BeOne Medicines

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

23. november 2026

Primær fullføring (Antatt)

27. februar 2029

Studiet fullført (Antatt)

27. februar 2029

Datoer for studieregistrering

Først innsendt

23. oktober 2026

Først innsendt som oppfylte QC-kriteriene

23. oktober 2026

Først lagt ut (Faktiske)

29. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Andre studie-ID-numre

  • BON-C1393-101

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.

BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.

Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

IPD-delingstidsramme

See plan description

Tilgangskriterier for IPD-deling

See plan description

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE
  • CSR

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .